A total of 161 patients transplanted between 1978 and 1991 and who had survived at least 2 years after allogeneic bone marrow transplantation (BMT) were studied. Of 161 surviving patients, 28 (17.4%) were positive for hepatitis C virus (HCV) either by serology or polymerase chain reaction (PCR). Twenty-five patients were positive for HCV RNA by PCR, and 26 of the 28 patients had HCV antibodies detected by enzyme-linked immunosorbent assay (ELISA). The median follow-up time of HCV-positive patients was 6.1 years (range, 2.8 to 14.0 years). There was no difference in the frequency or degree of liver dysfunction between patients L IVER FUNCTION abnormalities are frequent after allogeneic bone marrow transplantation (BMT). The differential diagnoses include acute and chronic graft-versushost disease (GVHD), venoocclusive disease (VOD), toxic liver cell damage caused by chemotherapy, and viral infections caused by hepatitis B and C viruses, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus.' Hepatitis C virus (HCV) is the most common cause of transfusionassociated hepatitis and the main cause of non-A, non-B hepatitis. HCV infection is common among patients who, before routine screening of blood donors with second generation serologic tests was introduced, had received repeated blood or platelet transfusions. Thus, BMT recipients have been at high risk for HCV infection. The acute hepatitis caused by HCV is frequently mild, but approximately 60% develop chronic hepatitis.' In immunocompetent individuals, long-term follow up (an average of 18 years) has shown a small increase in deaths related to liver disease.' Less is known about long-term effects of HCV in BMT recipients. The aim of this study was to assess the influence of HCV infection on short-and long-term morbidity after allogeneic BMT.
L
IVER FUNCTION abnormalities are frequent after allogeneic bone marrow transplantation (BMT). The differential diagnoses include acute and chronic graft-versushost disease (GVHD), venoocclusive disease (VOD), toxic liver cell damage caused by chemotherapy, and viral infections caused by hepatitis B and C viruses, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus.' Hepatitis C virus (HCV) is the most common cause of transfusionassociated hepatitis and the main cause of non-A, non-B hepatitis. HCV infection is common among patients who, before routine screening of blood donors with second generation serologic tests was introduced, had received repeated blood or platelet transfusions. Thus, BMT recipients have been at high risk for HCV infection. The acute hepatitis caused by HCV is frequently mild, but approximately 60% develop chronic hepatitis.' In immunocompetent individuals, long-term follow up (an average of 18 years) has shown a small increase in deaths related to liver disease.' Less is known about long-term effects of HCV in BMT recipients. The aim of this study was to assess the influence of HCV infection on short-and long-term morbidity after allogeneic BMT.
PATIENTS AND METHODS

Patients.
A total of 184 consecutive patients transplanted between 1978 and 1991 and who had a disease-free survival of at least 2 years after BMT were eligible for study. Twenty-three patients who did not return for follow up during the study period were excluded. Thus, 161 patients were included in this study population.
Forty patients had a follow-up time of between 2 and 4 years, 64 between 4 and 8 years, 45 between 8 and 12 years, and 12 patients had a follow up of longer than 12 years. The long-term follow up of these patients included at least yearly visits for the first 5 years after BMT and, thereafter, at least every other year. At the followup visits, liver function tests were routinely performed. Liver biopsies were performed when clinically indicated.
BMT procedure. The BMT procedure has been described in detail previo~sly.~~' Patients with aplastic anemia and HLA-identical sibling donors were conditioned with cyclophosphamide, 50 mgkg for 4 consecutive days. Antithymocyte globulin was added for a few patients. Patients with metabolic diseases were conditioned with busulfan and cycl~phosphamide.~ Patients with malignant diseases were conditioned with 10 Gy or 7.5 Gy (T cell-depleted patients) of total body irradiation (TBI), in most cases combined with cyclophosphamide.' During the later part of the study period, the combination of busulphan, 4 mgkg for 4 consecutive days, followed by cyclophosphamide, 60 mgkg for 2 days, was used. Methotrexate, cyclosporin, cyclosporin plus methotrexate, or T-cell depletion was used as GVHD prophylaxis. These different regimens were described in detail previously.'.' Acute GVHD was graded from 0 to IV according to previously published criteria? Chronic GVHD was defined according to the standards of Shulman et al* and Schubert et a19 and was verified by biopsies.
Virology. Serum samples from all patients included in the study were examined for the presence of HCV antibodies and for HCV RNA by polymerase chain reaction (PCR). The follow-up sera were obtained from the last follow-up visit to the clinic and had not been stored for more than 12 months at the time of analysis. Pretransplant sera were examined when available and when the time from BMT to analysis did not exceed 5 years.
Routine screening for HCV antibodies was performed by second generation enzyme immunoassay (EIA; Abbott Laboratories, Chicago, IL) and further examined by four-band recombinant immunoblot assay (RIBA; Chiron Corp, Emeryville, CA) or HCV EIA supplementary assay (Abbott Laboratories). The results were assessed as recommended by the manufacturers. Thus, reactivity to two or more viral recombinant antigens or peptides was considered as a positive, reactivity to one peptide as an indeterminate, and reactivity to none of the peptides as a negative result.
PCR for HCV RNA was performed according to Yun et al.'" RNA was extracted using a modified single-step acid guanidinium thiocyanate-phenol-chloroform method. Thereafter, a combined reverse transcription and nested PCR technique was used.
To be regarded as HCV-positive in this study, the patients must was positive in 24 of these patients, three patients were PCRnegative, and one patient was not tested by PCR. Two of the PCR-negative patients had received antiviral therapy. In addition, one patient who was PCR-positive at 12 and 24 months after BMT became PCR-negative at 36 months after BMT without having received antiviral therapy. Two patients who were ELISA-negative were positive by PCR.
Pretransplant liver disease. Altogether, 37 patients were tested by PCR before BMT. Thirty-two patients were PCRnegative and five, PCR-positive. Thus, 5 of the 28 patients who tested positive after BMT were already positive for HCV RNA before BMT. None of these patients spontaneously became HCV-negative by PCR after BMT. However, three patients were given anti-HCV treatment (see below). An additional five patients had a history of transfusion-associated hepatitis but were not tested by PCR before BMT. These 10 patients will for the purpose of this study be regarded as having a proven or probable HCV infection before transplant (group A).
Ten patients were negative by PCR before BMT. An additional eight patients who were not tested by PCR had normal liver function tests before transplant and no history of hepatitis during their previous medical history. Many of these patients had never received transfusions before the BMT. These 18 patients will for the purpose of this study be regarded as having no evidence of being infected with HCV before the transplant (group B).
Liver dysfunction between BMT and 3 months after BMT. Twenty-five of the 28 patients had some degree of liver dysfunction during the first 3 months after BMT: all 10 patients in group A and 15 of 18 patients in group B [difference not significant (NS)]. Five of 10 patients in group A had their most severe degree of dysfunction during this period (two patients with mild, two patients with moderate, and one patient with severe dysfunction). None of the patients in this group fulfilled the definition of VOD. Nine of 18 patients in group B had their most severe degree of dysfunction during this period (two patients had mild degree and seven had a moderate degree of liver dysfunction). Two patients in this group had clinical syndromes fulfilling the criteria for mild VOD of the liver. Both were PCR-negative before BMT.
Liver dysfunction between 3 months and 2 years after BMT. Five of 10 patients in group A had their most severe degree of dysfunction during this period. All had moderate degrees of liver dysfunction. Three of these five patients developed their liver dysfunction at a time when their ongoing immunosuppression had been either discontinued or tapered significantly. Six of 18 patients in group B had their most severe degree of dysfunction during this period. Five of these patients had severe liver dysfunction. All five patients developed a clinical picture consistent with acute viral hepatitis at the time of decreased or discontinued immunosuppression. Thus, there was a correlation between decreased immunosuppression and acute hepatitis in five of six patients who developed severe liver dysfunction at any time posttransplant. Liver function at long-term follow up. Twenty-seven of 28 patients are alive at a median of 5.7 years (range, 2.8 to 14.0 years) after BMT. One patient has died of AIDS 10 years after BMT, with the human immunodeficiency virus type 1 (HIV-1) infection transmitted through blood transfusions after the BMT. No patient has clinical signs of liver failure. Eleven patients have normal S-ALAT levels at latest follow up, 14 patients have S-ALAT levels between ULN and three times the ULN, and five patients have S-ALAT levels of more than three times the ULN ( Table 2) . No test could predict the degree of liver function abnormality (data not shown). However, all four PCR-negative patients had normal S-ALAT levels.
The relations between chronic GVHD, HCV positivity, and S-ALAT and serum alkaline phosphatase (S-ALP) levels are shown in Table 3 . Only 13% of patients who were HCVpositive and had active chronic GVHD at follow up had normal S-ALAT levels, as compared with 73% of patients who were HCV-negative and who did not have chronic GVHD. There was no relation between abnormal S-ALP and either chronic GVHD or HCV positivity in adult patients. Children were not included in this analysis due to the variation in normal values for ALP in different age groups. greater than 50%, and one patient did not respond to treatment. One patient relapsed with abnormal s-ALAT levels after cessation of therapy. This patient had received a BMT due to chronic myeloid leukemia (CML), and at the time of interferon therapy, the bone marrow showed cytogenetic relapse. During a-interferon therapy, the patient went into cytogenetic remission and has remained in remission during 24 months of follow up. One patient who was PCR-positive before BMT received long-term ribavirin therapy and is now PCR-negative 36 months after BMT and 12 months after stopping ribavirin therapy.
Two patients became PCR-negative during therapy and have remained negative during 6 and 30 months of follow up, respectively. One patient became PCR-negative during therapy but has not yet been tested by PCR after cessation of interferon. One patient was not tested during therapy but is PCR-positive at latest follow up. One patient has remained PCR-positive during therapy. There was no development or exacerbation of chronic GVHD during a-interferon treatment.
Liver biopsies. Fifteen patients have had a total of 23 liver biopsies performed after BMT. Twenty-two of these biopsies were available for evaluation. Six patients had biopsies during the first year after BMT. Two biopsies were interpreted as acute hepatitis, two as GVHD, one as hemosiderosis, and one as a combination of GVHD and hepatitis.
Nine patients had a total of 17 biopsies performed later than 1 year after BMT. One of the patients had late-developing hepatitis, and two subsequent biopsies were consistent with acute viral hepatitis. Biopsies in this patient performed 2 and 5 years after the acute hepatitis showed chronic persistent hepatitis (CPH). Two patients had biopsies before and after a-interferon therapy, and in both patients, the first biopsy was interpreted as chronic active hepatitis (CAH). However, the biopsies performed after a-interferon therapy were interpreted as CPH. The remaining patients have had one biopsy each. Five biopsies were interpreted as CPH, one as CAH, one as chronic GVHD, one as cholangitis, and one as normal. The normal biopsy was from a PCR-positive patient 10 years after BMT. None of the patients have had biopsies showing liver cirrhosis. The median time from BMT to the latest liver biopsy (with the a-interferon-treated patients censored at the time of initiation of therapy) was 4 Treatment with a-inte$eron. Five patients received reyears (range, 2 to 10 years). combinant a-interferon at a dose of 3 X lo6 U three times Other symptoms. One patient developed a Guillainper week. Three patients responded with normalized
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Barr6 syndrome 4 months after BMT and 1 month after ALAT levels, one patient's S-ALAT level decreased by acute hepatitis. The symptoms resolved without therapy. One 
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For personal use only. on October 22, 2017. by guest www.bloodjournal.org From patient has developed cryoglobulinemia 8 years after allogeneic BMT. Four of 28 (14%) HCV-positive patients have developed signs of exocrine pancreas insufficiency with steatorrhea. This is a rare complication of BMT, and the corresponding frequency among long-term survivors without signs of HCV infection was 1 of 133 (P = .001; x ' with Yates' correction). Another possible risk factor for exocrine pancreas insufficiency could be irradiation. All five patients had received TBI, but there was no significant difference between the frequency of exocrine pancreas insufficiency in patients with or without T B 1 conditioning.
DISCUSSION
A number of studies have been published describing the frequency of HCV-positive patients after BMT.I2-l5 In a study performed with first-generation serologic tests, we found a frequency of HCV infection of 10%.l2 These tests gave both false-positive and false-negative results. The introduction of second-generation tests and the use of supplementary tests such as RIBA have improved the reliability of serologic assays. However, the frequency of HCV seropositive patients varied from 3% to 28% in different studies when the second-generation tests were used, presumably depending on variations in the prevalence of HCV in the blood donor pool in different co~ntries.'~"' We found in the present study a frequency of 17.4% when serology as well as PCR were used to define HCV-infected patients. It is important to use different diagnostic tests, as 7% of the patients who were PCR-positive were negative by ELISA. Furthermore, all eight patients who had indeterminate supplementary tests were positive by PCR. Similar results have been shown previously.16 It is well known that BMT patients are frequently not able to mount a serologic response to virus infections occumng during the first year after BMT, for example, CMV and varicella-zoster virus. Thus, serologic tests will underestimate the true frequency of HCV in BMT patients.
The time from BMT did not influence the risk for being HCV-positive by PCR. Of 25 tested patients who had not received antiviral therapy, 24 were positive by HCV RNA, with the longest follow up from BMT of 14 years. This is in agreement with data in non-immunocompromised patients. Reuter et all' showed that 97% of HCV-seropositive patients who had a long history of chronic hepatitis were also positive by PCR.
Liver dysfunction is very common after allogeneic BMT. HCV infection has been associated with liver failure after BMT. Recently, Frickhofen et all8 reported a very high risk for fatal early VOD in patients who were HCV-infected before BMT. In our experience, of 10 patients who were HCV-positive by PCR before BMT, only one developed severe VOD. Furthermore, only 1 of 13 patients who developed lethal VOD was HCV RNA-positive before BMT. 19 We found that during the first 3 months after BMT, liver dysfunction was usually mild with fivefold to 10-fold increases in s-ALAT. The problem during this phase was mainly to differentiate between hepatitis and acute GVHD. However, the observation of Frickhofen et all8 necessitates careful assessment of the indication for BMT in pretransplant HCV-positive patients and possibly the instigation of antiviral therapy during the transplant procedure. Of greater importance was the occurrance of late hepatitis, which in most cases coincided with a decrease in or discontinuation of immunosuppressive therapy. This is a described complication in patients with hepatitis B and has also been described for HCV in BMT Another aim of our study was to determine the impact of HCV on long-term survivors; particularly, if HCV in this immunocompromised patient population caused progressive liver disease in a higher frequency than in non-immunocompromised patients. In this aspect, our results were encouraging. So far, there are no signs of severe progressive liver disease among the patients included in this study. We have not as a routine performed biopsies on all patients with normal or very slightly abnormal S-ALAT levels. One problem in the interpretation of the biopsies in patients who have undergone allogeneic BMT is the differential diagnosis of chronic GVHD. If the presence of the diagnostic signs for CAH and cirrhosis is used as the definition of more severe disease, seven of nine patients had a mild histologic picture of CPWGVHD, and no biopsy showed development of liver cirrhosis. Alter et a12 showed in a prospective study of non-A, non-B hepatitis that 100% of patients who presumably had been infected by blood transfusion developed CAH with a follow up of less than 48 months. In our patients, all of whom can be assumed to have been infected by blood transfusions, only two of nine patients showed CAH, with the longest follow up from BMT to biopsy of 10 years. Furthermore, several of the patients were infected before BMT, which makes the true time from infection to last follow up and biopsy even longer. It is possible that this rather benign and slow progression to severe liver disease in our patients is due to the fact that most patients were severely immunosuppressed at the time of infection. Larger numbers of patients and longer follow up are needed to further analyze this question. It might be argued that because we looked at long-term survivors, HCV might have contributed to fatal outcome earlier during follow up. However, no patient at our center has died of liver failure occurring later than 6 months after BMT. Thus, it is unlikely that HCV has influenced late mortality.
HCV has been implicated in extrahepatic diseases, particularly cryoglob~linemia.~~ There have also been speculations about HCV as one contributing factor to Sjogren's syndrome. One of our patients has a history consistent with cryoglobulinemia, and several have been diagnosed with chronic GVHD on the basis of abnormalities in liver function and decreased function of lacrimal and salivary glands (sicca syndrome). Virus infections, in particular the herpes viruses, have been implicated as a cofactor in chronic GVHD.24,25 In addition, we have noted that exocrine pancreas insufficiency was more common in patients infected by HCV. It could be speculated that HCV itself might infect and damage lacrimal or salivary glands or that an allogeneic response directed against host antigens in association with HCV might contribute to these symptoms. Finally, HCV can probably be added to the long list of viral infections able to predispose for the development of Guillain Barr6 syndrome.
The results of this study show that HCV infection was
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From common among long-term survivors after allogeneic BMT, but in most patients, the liver dysfunction was mild. These data indicate that HCV is not a major contributing factor to morbidity and mortality during the first 5 to 10 years after allogeneic BMT.
